Introduction
The mammalian SWI/SNF complexes are chromatin remodelers that regulate gene expression by evicting nucleosomes at gene promoters. SWI/SNF subunits, particularly AT-rich interactive domain 1 (encoded by the ARID1A), are known to be involved in transcriptional regulation, DNA replication and DNA damage repair 1 . Mutations, translocations and deletions in human cancers lead to defective SWI/SNF complex assembly and recruitment, abnormal gene silencing and tumor development 2, 3 . Recent large-scale and integrated multi-platform sequencing analyses of pancreatic cancer ductal adenocarcinoma (PDAC) have revealed ARID1A mutations in ~6% of cases 4 , besides predominant somatic mutations of KRAS, TP53, SMAD4 and CDKN2A.
These predicted loss-of-function alterations has led to the prevailing assumption that ARID1A behaves as a classic tumor suppressor gene (TSG), likely demonstrating genetic cooperation with mutant KRAS in pancreatic tumorigenesis. In fact, several recent genetically engineered mouse (GEM) models have been developed, largely based on this premise, with the investigators generating mice with pancreas-specific Arid1a loss and mutant Kras expression [5] [6] [7] [8] .
Predominantly, these GEM models showed appearance of intraductal papillary mucinous neoplasms (IPMNs), a bona fide precursor lesion of PDAC, with only one study reporting progression to PDAC on the backdrop of IPMNs in 20% of these mice. This led the investigators to conclude that loss of Arid1a in the context of mutant Kras results in an IPMN -PDAC pathway to invasive cancer in the pancreas 5 . However, rather inexplicably, other studies have also shown that the rate of ARID1A mutation or loss of expression in human IPMN samples is substantially higher than in human PDAC samples 5, 7, 9, 10 . This stands in stark contrast to all of the wellestablished TSGs in PDAC (particularly TP53, SMAD4 and CDKN2A), which consistently demonstrate an increasing frequency of abnormalities in the multistep progression from precursors to invasive cancer 4, 11 . In order to functionally address this paradox, we revisited the role of ARID1A loss in multistep pancreatic carcinogenesis. Consistent with prior reports, pancreatic exocrine deletion of Arid1a in conjunction with mutant Kras expression led to an IPMNpredominant histology, alongside non-cystic pancreatic intraepithelial neoplasia (PanINs) precursor lesions. Surprisingly, the lesions arising in "KAC" mice demonstrate markedly reduced proliferative rate, in contrast to "KC" mice with retained Arid1a function. This growth suppression was phenocopied ex vivo in murine and human cell lines with CRISPR-induced deletion of ARID1A, accompanied by significant impairment in DNA damage response (DDR). A compensatory upregulation of the SWI/SNF homolog ARID1B is observed in ARID1A mutant cells, which albeit not rescuing the growth arrest or DDR defect, results in a "synthetic essentiality" 12 , creating a requirement of sustained Arid1b expression for survival, a facet that can be exploited as a therapeutic target. In a subset of "KAC" mice, we eventually observe the development of aggressive PDAC, accompanied by deregulation of a diverse array of putative escape mechanisms, including Myc overexpression or low Trp53 expression. Our functional data establishes that ARID1A does not behave as a classic TSG, but rather, its loss within pancreatic precursors restrains progression, unless circumvented by one of several escape mechanisms.
Our findings reconcile the observed discrepancy in rates of Arid1a loss between human IPMNs and PDAC, and identify several potential targetable opportunities in tumors with ARID1A mutations.
MATERIALS AND METHODS
Detailed methods are described in the Supplementary Materials and Methods. Primary antibodies are listed in Supplementary Table 4 . Primer Sequences are described in Supplementary Table 5 .
Genetically Engineered Mice
All mice experiments were approved by UT MD Anderson Institutional Animal Care and Use Committee (IACUC) and performed in accordance with the NIH guidelines for use and care of live animals under the protocol number 00001222-RN01. LSL-KrasG12D, Ptf1a-Cre/+, ARID1A fl/fl mice have been described before and were purchased from Jackson laboratories. Genotyping PCR was performed from genomic DNA from tails using standard protocol of N-Extract kit (Sigma).
Cell culture
Murine "KPC" cell line was derived from a spontaneous tumor arising in a female LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ ;Pdx-1-Cre ("KPC") mouse; "KC" and "KAC" cell lines were isolated from spontaneous tumors arising in LSL-Kras G12D/+ ;Pdx-1-Cre and LSL-Kras G12D/+ ;ARID1a fl/fl ;Ptf1a-Cre mice, respectively and their epithelial origin confirmed by genomic PCR for Cre-mediated Kras recombination. Patient-derived low passage cell line Pa04 was cultured as described before 13 . Cells were maintained at 37°C in humidified 5% CO2 incubator and cultured in DMEM (Sigma-Aldrich, Cat#D6429) supplemented with 2 mM L-glutamine (Sigma-Aldrich, Cat#G7513), 10% FBS (Sigma-Aldrich, Cat#F2442), and 100ug/ml Pen-Strep (Corning, Cat# 30002CI). All cell lines were tested routinely for mycoplasma contamination.
ARID1A Deletion by CRISPR/Cas9
sgRNA cassette was generated using the CRISPR design tool (http://crispr.mit.edu). The sequence of various sgRNAs were Mouse-Ex.2a sgRNA (GGTCCCTGTTGTTGCGAGTA),
Mouse-Ex3a sgRNA (GCCCTGCTGGCCATACGCAC), Human-Ex1a sgRNA (GATCCCCGCTGTCTCGTCCG), Human-Ex1b sgRNA (TTGTTGGGCCCCTCCCGAGG). The sgRNAs were cloned into the pX459 (pSpCas9 (BB)-2A-Puro) plasmid vector (Addgene, Cat#62988). Mouse or human cell lines were transfected with the abovementioned plasmids using Lipofectamine 3000, and positive cells selected in the presence of 1.5 μg/ml puromycin.
Determination of cell growth and morphology
Cellular morphology and proliferation were assessed using Incucyte live cell imager (Sartorius) and images analysed with the IncuCyte HD software. Proliferation was measured through quantitative kinetic processing metrics derived from time-lapse image acquisition and presented as percentage of culture confluence over time. For experiments where cells underwent change in morphology due to effect of a drug, cells stably expressing the inert RFP in the nuclei (transfected with IncuCyte NucLight Red Lentivirus Reagent; Essen Bioscience, Cat#4476) were used to perform quantitative kinetic metrics and evaluate proliferation, expressed as count/well.
3D cultures for Colony formation
Anchorage-independent growth assay in soft agar was performed as described before 13 . Briefly, cells were seeded at a density of 1000 cells/well in 12-well plates with drug treatments on the next day. After two weeks, plates were fixed and stained with 0.005% Crystal violet solution 
RESULTS

Loss of Arid1a restrains expansion and progression of Ras-induced pancreatic precursor lesions
Since Arid1a is a critical gene from the standpoint of embryonic development 14, 15 , we conditionally deleted Arid1a in the pancreatic epithelial compartment by crossing Ptf1a-Cre 16 and
Arid1a fl/fl mice 14 to derive Arid1a fl/fl ;Ptf1a-Cre ("AC") mice. These "AC" mice survived until euthanasia when 80 week-old, however, histology at 8-weeks showed parenchymal atrophy with fatty replacement accompanied by inflammation, characteristic of pancreatitis, followed by appearance of acinar to ductal metaplasia (ADM), dilated ducts, and microscopic cysts lined by mucinous epithelium at 16-weeks (Supplementary Figure S1A) . Histology at 40-week showed additional fluid-filled macroscopic cysts, along with few focal low-grade PanINs (LG-PanINs) (Supplementary Figure S1B) . Immunohistochemistry (IHC) confirmed lack of Arid1a expression in epithelium of "AC" mice (Supplementary Figure S1C) . Next, LSL-Kras G12D ;Arid1a fl/fl ;Ptf1a-Cre ("KAC") mice were generated by crossing Arid1a fl/fl ;Ptf1a-Cre ("AC") mice with Lox-stop-lox Kras G12D mice 17 . Both "KAC" and littermate control "KC" mice (LSL-Kras G12D ;Ptf1a-Cre) were necropsied either at first sign of distress or at periodic age intervals to perform histological assessment of pancreatic pathology. Numerous groups have described the natural history of disease in "KC" mice, which show histological pancreatic lesions, similar to human ADM and LG-PanINs around 16 weeks of age. These lesions progress to high-grade PanINs (HG-PanINs) with age and infrequently (<10% of cases) to frank PDAC after 1 year. In stark contrast with "KC", necropsy of "KAC" mice revealed large fluid-filled cysts in "KAC" mice at 8 weeks, which increased in size and distribution with age ( Figure 1A-B ). Histological analysis of 8-weeks old pancreas showed extensive parenchymal replacement by mucinous cysts resembling low-grade branched duct gastric type IPMN (LG-IPMN) in humans, admixed with LG-PanINs ( Figure 1A) . Pancreas at 8-20-weeks showed LG-IPMN, ADM and LG-PanINs adjacent to normal appearing parenchyma ( Figure 1A) . With progressing age (20-32 weeks), the average area comprising of normal parenchyma gradually decreased in "KAC" pancreas (20.6% at 8-10 weeks, 7.7% at 16-20 weeks, 3.4% at 24-28 weeks), mostly replaced by LG-IPMNs, LG-PanINs and ADM lesions ( Figure 1B) . Lack of Arid1a expression in the precursor lesions arising in the "KAC" mice was confirmed by IHC ( Supplementary Figure S2A-B) . To assess the growth potential of precursor lesions in "KC" and "KAC" mice, we performed IHC for Ki-67 on age-matched pancreatic tissues.
As expected in "KC" mice, an average of 40-50% of PanINs showed nuclear Ki-67 staining, in contrast with ~5% Ki-67 staining in both IPMNs and PanINs of "KAC" mice, indicating lower proliferative potential of these cells (Figure 1C, Supplementary Figure S2C ). This lower proliferative state was complemented by a higher percentage of precursor lesions in "KAC"
pancreata showing strong staining for cleaved caspase-3, indicating ongoing apoptosis in these cells ( Figure 1D , Early; Supplementary Figure S2D , Late). This suggested that Arid1a is critical for growth of pancreatic premalignant lesions during early stages of disease development.
Despite restrained growth of precursor lesions, we witnessed a discernible shift in mortality of "KAC" mice with subsequent age (Figure 1E ; 84% survival at 32 weeks versus 48% at 38 weeks).
Histological assessment of pancreatic tissue revealed appearance of isolated foci of welldifferentiated PDAC surrounded by confluent areas of LG-IPMNs, scattered ADMs and LG-PanINs in 4/11 mice ( Figure 1F) . With progressing age, survival of "KAC" mice reduced further to 36%, accompanied by growth of unifocal PDAC in 18/30 "KAC" mice, which were topographically distinct from LG-IPMN, LG-PanINs and rest of pancreatic tissue. Most of these PDAC were well-differentiated and metastasized to liver and lung ( Figure 1G) . Notably, in these older mice, PDAC were still accompanied by LG-IPMN and LG-PanINs, instead of high grade precursor lesions, which was in stark contrast with stepwise progression of lesions with age from low-to high-grade PanINs in "KC" mice.
Loss of ARID1A expression in human IPMNs with low-grade dysplasia
Due to dominance of LG-IPMNs of gastric subtype in Arid1a-null "KAC" mice, we assessed for loss of expression of ARID1A by IHC in a collection of 53 human IPMN sections representing various histological subtypes and dysplasia grades. Notably, loss of ARID1A expression was restricted only to low grade IPMNs of gastric subtype (Figure 2A- and pancreato-biliary subtypes. Indeed, the high-grade IPMNs had an even stronger intensity of nuclear ARID1A expression than seen in adjacent normal ductal epithelium, suggesting an ongoing requirement for Arid1a function, in order to manifest as dysplastic progression. Even in IPMNs cases with mixed histological grades, the low-grade epithelium lacked ARID1A expression while the region with progression to high-grade dysplasia retained strong expression ( Figure 2C) .
These findings from human IPMNs supported our GEM model data that loss of Arid1a might paradoxically constrain the progression of low grade IPMNs into higher-grade lesions.
Arid1a Loss is detrimental to the growth of established PDAC lines
To assess the direct functional role of Arid1a without other compensatory molecular events appearing during autochthonous progression in the "KAC" GEM model, we employed CRISPR-Cas9 based approach to delete this gene in the Arid1a-expressing PDAC lines established from "KC" and "KPC" mice. To this end, "KC" and "KPC" cells were transfected with two independent CRISPR-Cas9 sgRNAs plasmids, targeting exons 2 and 3 of the murine Arid1a gene, respectively. Genomic PCR sequencing and immunoblot analysis in CRISPR-ARID1A cells confirmed Arid1a deletion in puromycin-selected clones ( Supplementary Fig. S3A and Figure   3A ). Although CRISPR-ARID1A cells did not show any changes in cellular morphology ( Supplementary Fig. S3B ), they were both significantly growth retarded in monolayer cultures ("KC" and "KPC" CRISPR-ARID1A cells showed 70% and 50% reduced cell growth, respectively; P<0.0001; Figure 3B ). Similarly, both "KC" and "KPC" CRISPR-ARID1A cells showed greater than 50% decrease in number of anchorage-independent colonies with 14-day culture in soft agar ( Figure 3C -D, P<0.01). Cell cycle analysis showed that Arid1a deletion caused significant G1 arrest in both "KC" and "KPC" cells ( Figure 3E) . This growth defect of CRISPR-ARID1A in both To characterize autochthonous Arid1a-null IPMN cells, we attempted to establish cell lines from "KAC" mice with only IPMN lesions. Notably, these cells failed to grow stably in culture despite repeated attempts, consistent with our observed low Ki-67 staining and thus, low proliferative potential of Arid1a-null cells in vivo. However, we were able to establish PDAC cell lines from an autochthonous primary tumor (""KAC"-P") and the matched liver metastasis (""KAC"-L") from a 12-month old "KAC" mouse with invasive cancer. For subsequent experiments, we also used the aforementioned parental "KC" and "KPC" lines as orthogonal controls for "conventional" PDAC.
Growth characteristics of these cell lines were compared in both 2D monolayer cultures and 3D aggregates in soft agar. While "KC" and "KPC" cells grew in clustered colonies with tight cell-cell adhesion, both autochthonous "KAC" lines showed elongated, spindle-shaped morphologies, characteristic of mesenchymal cells (Figure 4A ). Gene expression analysis by semi-quantitative RT 2 -PCR showed increased expression of epithelial-mesenchymal transition (EMT)-associated genes in "KAC" cells ( Supplementary Fig. S4A ). Despite the difference in morphology, there was no significant difference in growth of the autochthonous "KAC" cells with "KC" or "KPC" cells, in either 2D or 3D cultures ( Figure 4B-C) , consistent with no difference in cell cycle progression between these lines ( Supplementary Fig. S4B ). To assess their in vivo growth characteristics, we implanted "KC", "KAC-P" and "KAC-L" cells orthotopically in the pancreas of athymic nude mice. Necropsy at 4 weeks post-injection showed no significant differences in the size of primary tumors among the groups at the macroscopic (data not shown) or microscopic levels, mirroring the well-differentiated grade of parental tumors (Supplementary Fig. S4C ). In contrast with these autochthonous cell lines, the CRISPR-ARID1A derivatives of both "KPC" and "KC" cells showed reduced expression of EMT-associated genes (Supplementary Fig. S3D ) and reduced migration, compared to the control cells ( Supplementary Fig. S3E -F).
Identification of candidate "escaper" mechanisms in autochthonous Arid1a-null PDAC cells
To elucidate potential "escaper" mechanisms that might allow autochthonous Arid1a-null "KAC-P" cells to circumvent the growth constraining effects of Arid1a loss, and progress to PDAC, we subjected the RNA from "KAC-P" and "KC" cells to global RNA sequencing (RNA-Seq). Among all differentially expressed transcripts (P<0.05), 2560 genes were upregulated and 2660 genes were downregulated at least 2-fold in "KAC"-P cells compared to "KC" cells, with Claudin 18
(Cldn18) being one of the highest differentially-expressed transcripts (Figure 4D , Supplementary Table 2 ). Interestingly, CLDN18 has been reported to be expressed in larger percentage of precursor lesions and indolent neoplasms, like PanINs and IPMNs, than in PDAC 18 .
We confirmed high Cldn18 expression at protein level in the autochthonous "KAC" lines, compared to "KC" and "KPC" cells ( Figure 4E) . Further, IHC on murine pancreatic tissues from "KAC" pancreases revealed robust expression in IPMN, PanIN and PDAC lesions ( Figure 4F ).
We also found strong CLDN18 expression in ARID1A-negative human PDAC tissues; stressing the inverse correlation between the expressions of these proteins (Figure 4G) . To elucidate whether CLDN18 transcription is directly altered via changes in chromatin accessibility upon
Arid1a loss, we generated de novo chromatin accessibility maps by performing ATAC-Seq in both "KC" and "KAC-P" cells. Data was validated by localization of ATAC-Seq peaks at known promoters and enhancers, available at ENCODE for the mouse genome, which confirmed the readily accessible chromatin surrounding the CLDN18 regulatory locus in "KAC-P" versus "KC" cells ( Figure 4H) . While we do not postulate CDN18 is an oncogenic "escaper" mechanism in "KAC" cells (especially as its upregulation is also seen in precursor lesions), our data identifies a facile membrane-based therapeutic target in human tumors with ARID1A mutations.
We performed gene set enrichment analysis (GSEA) of differentially expressed transcripts for known tumor-promoting networks that might serve as putative "escaper" mechanism(s) in "KAC-P" cells. GSEA identified enrichment of signatures positively associated with EMT (validated above, see Supplementary Fig. S4A ), a positive association with Myc and E2F activity and negative association with p53 and Ras signaling in "KAC"-P" cells ( Figure 5A-B ; Supplementary   Fig. S4D ). We confirmed loss of Arid1a and p53 protein expression, and diminished expression of Cdkn1A/p21 (canonical p53 target), phospho-p44/42 MAPK (ERK1/2) and total ERK1/2 (downstream targets of oncogenic Kras signaling) in "KAC" lines, compared to "KC" control ( Figure 5C, Supplementary Fig. S4E ). Further, consistent with the Myc activation signature in "KAC-P" cells, we noted a substantial increase in levels of TRP63 RNA and protein expression of ΔNp63α and γ isoforms in "KAC" cells compared to "KC" and "KPC" cells ( Figure 5C,   Supplementary Fig. S4E ), which has been recently shown to positively regulate MYC function 19 .
PDAC sections from the "KAC" mice also showed loss of p53 ( Figure 5D ) and strong MYC expression ( Figure 5E ), suggesting these as putative "escaper" mechanisms in the face of Arid1a loss. Parsing the RNA-Seq data, we identified pluripotency-associated transcription factors -Sox2 and Nanog -as significantly overexpressed in "KAC-P" cells ( Supplementary Table 2 Thus, we found that loss of Arid1a in an oncogenic Kras-driven GEM model ("KAC") restricts proliferative potential and constrains histological progression of precursor lesions at early stages.
Subsequently, PDAC develop in these mice due to a variety of candidate "escaper" mechanisms, likely under the selection pressure of oncogenic Ras.
Impaired DNA damage repair as a potential mechanism restraining neoplastic progression in Arid1a null cells
Reports in various solid cancers have shown that ARID1A mutations in cell lines are associated with compromised DNA damage repair, and enhanced sensitivity to agents inducing DNA double strand break (DSB), such as Cisplatin, or to the recently developed class of PARP inhibitors 24, 25 .
Indeed, prior studies have shown that SWI/SNF complexes often localize to sites of DSBs and facilitate chromatin decondensation following serine 139 phosphorylation of histone H2AX (P-H2AX) via ATM/ATR 26 . To our surprise, however, RNA-Seq data comparing "KAC" versus "KC" cells showed enrichment of gene signatures associated with enhanced DNA repair in "KAC" cells ( Supplementary Fig. S5A ). Underscoring this paradox, we found "KAC-P" cells to be relatively resistant to Cisplatin, compared to "KC" and "KPC" cells ( Supplementary Fig. S5B) . Similarly, contrary to other reports 25, 27 , "KAC" and ARID1a-deleted isogenic "KC" and "KPC" cell lines were also resistant to ATR inhibitor, either alone or in context of DNA damage ( Supplementary Fig   S5C-E) or to various PARP inhibitors (data not shown). This led us to postulate whether in the compendium of potential "escaper" mechanisms that lead to emergence of cancers in "KAC" mice, overcoming an inherent DNA repair defect could also be one, thereby providing survival advantage to a subset of Arid1a-null cells, and a permissive milieu for progression to PDAC. To test this hypothesis, we assessed DNA repair competency upon immediate Arid1a deletion, mediated by CRISPR-Cas9 in "KPC" and "KC" cells. Doxorubicin (Doxo) is a well-known chemotherapeutic agent known to induce DSBs and early activation of ATM leading to pH2AX and p53 activation 28 . Thus, pH2AX is an early and sensitive marker of DSB induction after Doxo treatment, when measured as foci by immunofluorescence 29 , along with foci formation by DNA damage-responsive protein 53BP1, whose recruitment to DSBs is dependent on the protein platform assembled in pH2AX-positive foci 30 . We first measured nuclear foci of pH2AX and 53BP1 proteins in Doxo-treated isogenic "KPC" cells with and without ARID1A expression. Even at baseline, we found significantly reduced levels of pH2AX and 53BP1 foci in CRISPR-ARID1A compared to CRISPR-EMPTY cells (Figure 6A and Supplementary Fig. S6A-B) . While control cells showed increased pH2AX and 53BP1-positive foci after 2 hours Doxo treatment (0.1µM), which came back to baseline state after 24 hours; the levels of foci in CRISPR-ARID1A cells were always significantly lower than control "KPC" cells, suggestive of an impaired DDR response.
However, when assessed in the setting of wild type TRP53 using isogenic "KC" cells, we did not find this decrease in the levels of either pH2AX or 53BP1 foci upon ARID1A deletion (Figure 6B and Supplementary Fig. S6A-C; "KC" CRISPR-EMPTY/ARID1A). For further evaluation of DNA damage and repair, we performed an orthogonal and highly sensitive comet assay, wherein quantification of the comet tail intensity relative to the head (% of DNA in tail) reflects the number of DNA breaks. Control cells from both "KPC" and "KC" cell lines (CRISPR-EMPTY) showed an initial increase of comets at 2h followed by reduction at 24h post-Doxo treatment, suggesting repair of damaged DNA (Figure 6C-F) . In contrast, CRISPR-ARID1A cells from both lines showed higher amount of damaged DNA at 24h, indicative of impaired DDR capability (Figure 6C-F) . This suggests that ARID1A is critical for DNA DSB repair, irrespective of active TRP53 signaling, but important for initial P-H2AX or 53BP1 foci formation in absence of active TRP53. Notably, confirming our premise of an "escaper" phenomenon in the "KAC" lines, while these cells had diminished levels of pH2AX or 53BP1 foci (Supplementary Fig. S7A-C) , reflecting their origin in the setting of Arid1a deficiency, they demonstrated comparable competency at post-Doxo DNA repair to both "KC" and "KPC" lines, as shown by Comet assay (Supplementary Fig. S7D-E) .
Loss of Arid1a causes impaired mismatch repair (MMR) in PDAC cells
Recently, ARID1A was suggested to be important for DNA mismatch repair (MMR) due to its interaction with the MMR protein, MSH2 in ovarian and colon cancer cell lines 31 . Thus, we examined the direct role of ARID1A in MMR using the isogenic CRISPR-ARID1A "KC" and "KPC" cell lines. ARID1A loss in both "KC" and "KPC" lines showed compensatory increase in expression of MSH6, PMS2 and MLH1 proteins, suggestive of impaired MMR function and an ongoing requirement for the MMR machinery (Figure 6G) . To confirm impaired MMR function, we utilized a quantitative functional MMR reporter assay 32 and found significantly reduced MMR capacity in the isogenic "KPC" line upon ARID1A deletion (Figure 6H) . Interestingly, and in contrast to the discordance between autochthonous and isogenic lines observed with DSB repair, both the "KAC-P" and "KAC-L" cell lines also showed strong increase in expression of MSH6 and PMS2 proteins ( Figure 6I) , and persistent functional impairment of MMR on the reporter assay ("KAC-P", P<0.01;
"KAC-L", P<0.05) compared to "KC" and "KPC" cells ( Figure 6J) . Thus, impaired MMR in the setting of ARID1A loss appears to be a tumor neutral phenomenon that persists in the autochthonous lines. This is in contrast to the defective DSB repair that appears to be at least partially responsible for restraining neoplastic progression within the pancreatic epithelium, such that acquisition of competent DSB repair is observed in autochthonous lines that arise under selective pressure.
Synthetic lethal targeting of Arid1a loss in PDAC
The concept of synthetic lethality has been widely exploited for cancer therapy since most cancers have loss-of-function mutations that are not readily targetable. ARID1B, a structurally related but mutually exclusive homolog of ARID1A in the SWI/SNF chromatin-remodeling complex, is a potential synthetic lethal vulnerability in ARID1A-mutant human cancers 33 . Indeed loss of ARID1B in ARID1A-deficient cells destabilizes the SWI/SNF complex and impairs proliferation in gastric and ovarian cancers 34 . To explore this vulnerability in PDAC using our GEM model, we first confirmed the expression of ARID1B in ARID1A-null cell lines. Remarkably, both "KAC" lines and isogenic lines with ARID1A deletion (CRISPR-ARID1A) showed increased expression of ARID1B, at both mRNA (Figure 7A-B ) and protein level (Figure 7C-D) , suggestive of a compensatory increase upon ARID1A loss. After confirming the successful knock down of Arid1b expression using short hairpin (pLK0-shARID1B) in both autochthonous and isogenic cells (Figure 7C-D) ,
we found that only the "KAC" cell lines showed ≥ 80% decrease in cell proliferation, compared to "KC" or "KPC" control cells upon Arid1b knockdown (Figure 7E) . Similarly, only ARID1A-null "KC" and "KPC" isogenic cell lines (CRISPR-ARID1A) showed reduction in cell proliferation compared to CRISPR-EMPTY control upon co-extinction of ARID1B (Figure 7F) . The effect of Arid1b knockdown was also remarkable in reducing anchorage-independent growth of "KAC" cell lines in 3D cultures (~70% reduction in colony count; Figure 7G and Supplementary Fig. S7A ). This indicates that ARID1B is a potential therapeutic target in ARID1A-deficient PDAC tumors, although currently there are no specific ARID1B inhibitors available for clinical trial. To overcome this concern, we explored other potential synthetic vulnerabilities of ARID1A-loss in our "KAC" model using commercially available small molecule inhibitors. Since MYC was one of the key "escaper" pathways upregulated in our "KAC" model, we tested the therapeutic vulnerability of "KAC" cells using 10058-F4, a specific small molecule inhibitor of MYC that prevents transactivation of MYC target gene expression 35 . In both monolayer and 3D spheroid cultures under ultralow-attachment conditions, "KAC" cell lines were significantly more vulnerable to 10058-F4 than control "KC" cells (Figure 7H, Supplementary Fig. S7B) . This "oncodependence" suggests MYC activation to be, at least in part, critical for survival of "escaper"
ARID1A-null cells. Recently, Arid1a mutation was reported as a biomarker for sensitivity of platinum-resistant urothelial carcinoma cells to Panobinostat-mediated HDAC targeting 36 .
Interestingly, GSEA of gene expression data in these cells showed enrichment for MYC, E2F targets, and DNA repair pathways, similar to our observed GSEA data in "KAC" cells. This provided us with a strong rationale to test synthetic lethality of Panobinostat in our "KAC" PDAC model. Remarkably, compared to control "KC"/"KPC" cell lines, "KAC" cells showed significantly better sensitivity to Panobinostat in both 2D monolayer cultures ( Figure 7I ) and 3D cultures for anchorage-independent growth (Supplementary Fig S7C-D) . Since Panobinostat is already a clinic-ready drug, this presents another potential opportunity for targeting Arid1a-null PDAC tumors.
HOMER analysis of our ATAC-Seq data showed enrichment in binding sites for PU.1 transcription factor in open chromatin regions of "KAC" compared to "KC" cells ( Supplementary Table 3 ),
suggesting higher functional activity of PU.1. Indeed, RNA-Seq and RT-PCR in the same population showed significant increase in levels of Csf1 (Supplementary Fig S7E) , which is a bona-fide target of PU.1. Using ENCODE database for mouse, we also found PU.1 binding sites in promoter of Cldn18, which was highly expressed in "KAC" cells ( Figure 5) . Utilizing a first-inclass small-molecule PU.1 inhibitor that specifically and allosterically interfere with PU.1chromatin binding 37 , we found "KAC" cells were significantly more sensitive in growth inhibition, compared to control "KC" and "KPC" cells ( Figure 7J) , presenting PU.1 as another synthetic lethal target in ARID1A-null PDAC cells.
In summary, we identified a novel context-dependent role of Arid1a in PDAC where immediate loss of Arid1a function in cells is growth restrictive, at least partially due to impaired DNA repair, but potentially creates opportunities for various compensatory oncogenic mechanisms to drive the disease progression. We also identified therapeutic vulnerabilities of Arid1a-mutant PDAC cells that can be readily tested in clinical studies in imminent future.
DISCUSSION
Deleterious mutations of ARID1A has been reported across multiple tumor types, resulting in the prevailing assumption that this SWI/SNF complex protein behaves as a prototypal tumor suppressor. However, DepMap analysis (https://depmap.org/portal/) of ARID1A using both CRISPR and RNAi screens in various cancer and pancreatic cancer cell lines showed dependency scores (CERES) <0, which indicates it is an essential gene for survival, as the score of -1 is comparable to the median of all pan-essential genes. Nonetheless, more nuanced evidence from both functional and correlative data is emerging that suggest a reassessment of the role of Arid1a as a relatively straightforward TSG might be warranted. For example, Zhu and colleagues demonstrated in murine models of hepatocellular carcinomas (HCCs) that sustained Arid1a expression was pro-tumorigenic, while loss of Arid1a was deleterious, during primary tumor formation 38 . In contrast, loss of Arid1a was typically observed in "late-stage" metastatic HCC models, underscoring a context dependent role during multistep carcinogenesis. In fact, this and other studies 39 42 . ARID1A mutations also correlated with better survival in uterine corpus endometrial carcinoma 43 . Within same patients of endometrial cancer, primary tumors retained ARID1A expression, while metastatic subclones lost it due to deleterious mutations 44 . The sum total of these data brings into question the preconceived notion that ARID1A is a prototypal TSG independent of genetic context and/or disease stage.
Some of these apparently paradoxical data points have also begun to accumulate in PDAC, wherein the frequency of ARID1A genomic alterations is significantly higher in precursor IPMNs, and in particular, low grade IPMNs, than that in higher grade precursors or invasive adenocarcinomas. For example, in the TCGA analysis, only 6% of PDAC harbor somatic ARID1A alterations 4 , while a recent single cell analysis of human IPMNs showed 40% with subclonal ARID1A mutations, all in the low-grade gastric type IPMNs 9 . In our own series, ~20% of patient IPMN samples have complete loss of ARID1A protein expression by IHC (consistent with bi-allelic inactivation), all occurring in low-grade gastric type IPMNs. In the COSMIC database, well differentiated pancreatic neuroendocrine tumors, which are indolent tumors with a proliferation rate <3% Ki-67 45 , carry a ~20% ARID1A mutation rate, more than three times higher frequency than the far more aggressive ductal adenocarcinomas (5.35%). Notably, these findings are in sharp contrast to well established TSGs, like TRP53 and CDKN2A, which demonstrate a progressive increase in rate of alterations from low grade to high grade precursors to invasive adenocarcinoma 11 , and where the frequency of mutations is typically higher in neoplasms at the aggressive end of the spectrum versus indolent tumors. These lines of evidence suggest that loss of Arid1a might not demonstrate outright genetic cooperation with oncogenic Ras in the pancreatic epithelium and thus warrant a careful reappraisal of the TSG role for ARID1A during multistep neoplastic progression ascribed in recently published GEM models [5] [6] [7] [8] .
Consistent with the published models, we found that Ptf1a-specific conditional loss of Arid1a in "AC" mice led to widespread pancreatitis and fatty replacement of post-mature parenchyma, suggesting that Arid1a is required for maintaining adult acinar homeostasis. This is comparable to conditional deletion of Arid1a leading to depletion of Lgr5-expressing mouse intestinal stem cells, disrupting intestinal homeostasis 46 . In mice with co-expression of mutant Kras G12D allele ("KAC"), the pancreas developed LG-IPMNs and LG-PanINs ubiquitously, with the former resembling gastric type IPMNs in patients, as has been previously reported 7, 8 . In contrast to "KC" mice, however, there was no stepwise progression of the LG precursors to HG precursor lesions, has also been reported to be repressed by p53 and the loss of p53 synergistically enhancing the Myc-induced tumorigenesis 47 . The appearance of these highly ranked aberrant signaling nodes was not unexpected, since the prior studies in autochthonous models have also reported upregulation of EMT-associated genes 8 and MYC activation within the resulting Arid1a-null cancers 7 and low ARID1A expression significantly correlated with low Ki-67 labeling index and negative p53 expression in breast cancer patients 48 . One interesting facet that emerged from the GSEA was downregulation of Ras signaling in the "KAC" lines, which was confirmed by assessment of MAPK activity. In this context, while MYC is considered a downstream effector of oncogenic Ras in PDAC, mediating its pleiotropic effects on tumor cell growth and metabolism 49, 50 , MYC can also substitute as a pivotal driver in the setting of "Ras independence", and the resulting tumors tend to be highly aggressive and chemoresistant 51, 52 .
The isogenic CRISPR-ARID1A clones of "KC" and "KPC" cells, developed in present study, were strikingly different in their behavior from the autochthonous "KAC" PDAC lines, which can be postulated to arise through an "escape" phenomenon from Arid1a deletion-induced growth constraint in vivo, likely under the selection pressure of oncogenic Ras and other secondary events within the pancreatic epithelium. Further, the compendium of tumor-promoting pathways in the autochthonous PDAC models (such as Myc upregulation and perturbation of p53 function) identified by us, and others 5, 7, 8 , are likely to be the molecular adaptations underlying this "escape" phenomenon. It is worth noting that in at least one prior study 8 , the "KAC" genotype rarely progressed to invasive cancers, with mice mostly developing IPMN precursors, unless additionally crossed to a mutant Trp53 background (providing one prototypal "escape" mechanism). Similarly, our recently published CRISPR-based mouse model of PDAC 53 showed Arid1a loss concurrent with oncogenic Kras mutation in adult acinar tissue only caused LG-PanINs, while emergence of well-differentiated PDAC in the same period required deletion of TRP53, irrespective of Arid1a loss. The distinction between the two scenarios -whether Arid1a loss cooperates with oncogenic Ras to induce PDAC formation (as proposed [5] [6] [7] [8] ), or invasive cancers arise via an "escape" phenomenon in the setting of growth constrained precursors -goes beyond semantics, given the occurrence of ARID1A mutations across a multitude of epithelial pre-cancers 54 .
What mechanism underlies the inability of Arid1a-deleted precursor lesions to robustly proliferate in vivo? Parsing the GSEA data on the "KAC" PDAC lines identified DNA repair as one of the highly ranked pathways, which was paradoxical, since numerous prior studies in preclinical models have suggested that the ARID1A protein (and other members of the BAF complex) is integral to repair of DNA DSBs [24] [25] [26] 55 . Specifically, Arid1a localizes to sites of DSBs through its interaction with DNA repair checkpoints, with loss of Arid1a leading to compromised homologous recombination repair (HR) and non-homologous end joining (NHEJ), the two major arms of DSB repair. Further, these studies have also shown increased sensitivity of cell lines with ARID1A mutations to DSB inducing agents like cisplatin, radiation and to PARP inhibitors 24, 25 . Surprisingly, our "KAC" cells were both relatively resistant to Cisplatin and PARP inhibitors (compared to the "KC" and "KPC" lines), and by the Comet assay, their DNA repair proficiency was comparable to these Arid1a wild type PDAC lines. This led us to postulate that acquisition of DNA repair capacity might be a crucial "escape" mechanism co-opted by "KAC" cells, and vice versa, impaired DNA repair a feature of Arid1a ablated precursors. We used the two CRISPR-ARID1A lines as a surrogate for assessing DNA repair capability, and found, indeed, that in response to doxorubicininduced DSBs, both isogenic derivatives of "KC" and "KPC" cells had compromised DNA repair on the Comet assay, compared to the respective parental controls. Interestingly, while the p53 status of the isogenic cells impacted the initial localization of pH2AX or 53BP1 to sites of DSBs, even the "KC" cells with wild type p53 demonstrated impaired DNA repair on the Comet assay.
Extrapolating from these findings, we hypothesize that early PDAC precursors (LG-IPMNs and
LG-PanINs), which retain p53 function, are nonetheless susceptible to impaired DNA repair in the face of Arid1a deletion. At the same time, there is likely to be an ongoing requirement for a competent DNA repair machinery in the "KAC" precursor lesions, given that mutant Ras is wellestablished for generating reactive oxygen species (ROS) and inducing a state of oxidative and genetic stress within the pancreatic epithelium 56, 57 . During the natural history of these mice,
Arid1a null precursor lesions that are unable to adapt, either "stall" or undergo apoptosis, while clones that can re-functionalize their repair machinery through secondary adaptations (e.g., loss of p53 expression) retain the capacity for progression to PDAC. The association between ARID1A mutations and MMR defects has been previously documented, most commonly in colorectal cancers 58, 59 . Similar to our observed increase in expression of MMR proteins in setting of Arid1a loss, overexpression of MMR proteins, such as PMS2, has been shown to disrupt mammalian MMR function causing genetic instability 60 . However, it is very likely that the functional impairment of MMR observed in the setting of Arid1a deletion is not a barrier to tumor progression that requires an "escape" (in contrast to other DNA repair defects), as there was no significant difference between the autochthonous "KPC" lines or the isogenic CRSIPR-ARID1A cells.
Finally, an area of considerable translational potential is the opportunity to develop targeted therapies against PDAC harboring ARID1A mutations. In light of our observations above, it is imperative that putative targets be distinguished into those that persist in the established PDAC, versus those that are present in precursor lesions, but are circumvented in established PDAC because of "escape" from Arid1a loss-induced growth constraints. For example, we posit that "escape" mechanisms are the basis for our observation that synthetic lethal effects described in other ARID1A mutant solid cancer models, such as susceptibility to PARP inhibition and cisplatin 24, 25, 55 , or to commercially available EZH2 inhibitors [61] [62] [63] , are absent in the autochthonous PDAC lines that have arisen in the setting of "escape". On the contrary, a striking "synthetic essentiality" 12 that is ubiquitously identified in the Arid1a mutant PDAC cells is the requirement of sustained ARID1B expression for survival. We observed increased expression of Arid1b in Arid1a-null cells irrespective of an "escape" setting (i.e., in both "KAC" cells and the CRISPRisogenic cells), reiterating this is a compensatory effect directly related to Arid1a deletion.
GeneHancer analysis 64 to occur for cancer progression in vivo. Another target whose expression appears to be inversely related to Arid1a levels is Claudin 18 (CLDN18) and parsing the ATAC-Seq in "KAC" cells demonstrated that the promoter/enhancer regions of both ARID1B and CLDN18 are replete with binding sites for the Pu.1 (SPI1) transcription factor (for example, the ARID1B promoter/enhancer had as many as 18 binding sites for Pu.1). We believe that Pu.1 could be one of the pivotal transcription factors driving the compendium of transcriptional alterations that are directly related to ARID1A loss in the pancreatic epithelium, including the compensatory expression of the synthetic essential, albeit currently "undruggable" Arid1b protein. In this regard, our proof of concept data with a first-in-class Pu.1 small molecule inhibitor demonstrates robust growth inhibition in "KAC" cells, and pending future validation studies, this might represent a facile pharmacological strategy for targeting ARID1A mutant PDAC. Additionally, Panobinostat, a potent pan-HDAC inhibitor, has been shown to cause growth arrest and apoptosis in cells from many cancer types including leukemia, by decreasing MYC expression and increasing expression of TRP53, CDKN1A (p21), DNA repair genes such as FANCG, FOXO3A, GADD45A, GADD45B, and GADD45G 65 . In ovarian cancer model, ARID1A loss inactivated the pro-apoptotic function of TRP53 by upregulating HDAC6, which directly deacetylated Lys120 of TRP53 66 . Thus, it was not surprising that Panobinostat was particularly effective against Arid1a-null "KAC" cells with elevated Myc signaling and decreased TRP53 and CDKN1A expression.
In conclusion, using a repertoire of GEM models, autochthonous and isogenic cell line models, we provide compelling evidence that ARID1A is not a prototypal TSG in PDAC pathogenesis. Au contraire, ARID1A loss induces a paradoxical growth constraint within the resulting low-grade cystic precursor lesions harboring mutant Ras, a finding we believe underlies the prolonged, indolent natural history of most gastric type IPMNs in patients. Loss of Arid1a compromises cellular DNA repair capability, which is likely compounded by the genotoxic stress of mutant Ras, leading to growth arrest and apoptosis. Eventually, through loss of p53, or upregulation of oncogenic networks like Myc or stem cell transcription factors, a subset of Arid1a-depleted precursor cells progress to frank adenocarcinomas. Our data reassesses the utility of therapeutic vulnerabilities previously described in other ARID1A mutant cancer models (e.g., DNA repair defects or microsatellite instability), in the setting of PDAC 24, 25, 55 , while describing novel opportunities for targeting this class of cancers in the clinic. 
